['hepatitis c virus']
['abt-493/abt-530']

        Inclusion Criteria:

          1. Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 4, 5, or
             6 infection.

          2. Chronic HCV infection.

          3. HCV treatment-naïve or treatment experienced (interferon [IFN] or pegylated interferon
             [pegIFN] with or without ribavirin [RBV]; sofosbuvir [SOF] plus RBV with or without
             pegIFN).

          4. Non-cirrhotic participants.

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any excipient
             of the study drugs.

          2. Female who is pregnant, planning to become pregnant during the study, or
             breastfeeding; or male whose partner is pregnant or planning to become pregnant during
             the study.

          3. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab).

          5. Co-infection with more than one HCV genotype.
      